Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Date:1/30/2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... their big brothers and sisters: they have a large surface ... same time a small number of atoms. This can produce ... of nanomaterials can suddenly become bendy, for instance, or a ... reddish. , New method developed , The chemical and ...
... 2011 Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... manufacture and sale of enzyme and protein products for ... that it has launched FibreZyme® G200, a ... quality and improve the economics of various pulp and ...
... Coast Angels (TCA), the nation,s largest angel ... including 12 new deals and 19 follow-on investments in ... investment leadership. TCA raised over $40 million ... $6 million through direct TCA investment and approximately $33.9 ...
Cached Biology Technology:3-D nanoparticle in atomic resolution 2Dyadic International Launches High Performance Enzyme for Pulp and Paper Industry Using New C1 Production Platform 2Tech Coast Angels Funds 31 Deals in 2010 and Highlights Three Profitable Exits 2
(Date:4/16/2014)... Wash. Geologic and soil processes are to blame ... Ohio, according to a study published recently in the ... of 842 soil samples from all corners of Ohio ... the screening level of concern recommended by the U.S. ... public, say the authors, who note that regulatory levels ...
(Date:4/15/2014)... Irvine neurobiologists have found that genetically modified neural stem ... of mice with the symptoms and pathology of Alzheimer,s ... Stem Cells Research and Therapy , and the ... mouse models. , Alzheimer,s disease, one of the ... of the protein amyloid-beta in the brain in the ...
(Date:4/15/2014)... early as 2020 how high sea levels will rise ... researchers including Florida International University scientist Rene Price. , ... (NSF) Florida Coastal Everglades Long-Term Ecological Research (LTER) site, ... from coral reefs to deserts, mountains to salt marshes ... rise is one of the most certain consequences of ...
Breaking Biology News(10 mins):Significant baseline levels of arsenic found in Ohio soils are due to natural processes 2Significant baseline levels of arsenic found in Ohio soils are due to natural processes 3Significant baseline levels of arsenic found in Ohio soils are due to natural processes 4UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Long-term predictions for Miami sea level rise could be available relatively soon 2
... and brings new dimensions into teaching and research. ... have in collaboration with the Finnish company Multitouch Ltd ... method is a combination of two technologies: web-based virtual ... is an entirely new way of performing microscopy: by ...
... of the European Congress on Osteoporosis & Osteoarthritis in ... 2nd ESCEO-IOF Servier Pierre D. Delmas Prize. ... Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) ... of Servier, honours an individual who has made outstanding ...
... (March 23, 2011) - A lot of chatter goes on ... happens between our ears. Researchers at McMaster University discovered ... brain plays an important role in the development of psychiatric ... including obesity. "The wave of the future is full ...
Cached Biology News:Big size multitouch display turned into a microscope 2ESCEO-IOF Servier Pierre D. Delmas Prize awarded to John. A. Kanis 2'Knowing it in your gut' is real 2
... solution is an isotonic, balanced salt solution. It ... permits the storage of whole blood at refrigerator ... equal volume of blood is collected into a ... mixed. The solution is placed in a refrigerator ...
... Hollandes is a fixative useful for routine ... It is stable and will decalcify small ... Hollande's can be stained successfully with most ... solution stabilizes red blood cell membranes and ...
... a single-channel sample processing head, an 8-channel ... dispenser all in one compact, affordable product. ... tips, the Precision XS autoclavable and organic ... for transferring larger volumes. Intuitive Precision Power ...
... The RapidPlate 96/384 workstation offers precise 96 ... scalable format. Utilizing 100ul and 200ul disposable ... delivers excellent accuracy and precision across a ... rotary deck includes two positions that enable ...
Biology Products: